Literature DB >> 6994767

Haemodynamics in hypertensive patients before and during guanfacine treatment.

N Schäfer, J Rauh, J Rosenthal.   

Abstract

1. The haemodynamic mechanisms underlying the antihypertensive effect of guanfacine during chronic oral administration were studied. 2. Ten patients with essential hypertension were submitted to haemodynamic measurements at rest and during exercise, before and after 12 weeks' treatment with guanfacine alone at a daily dose of between 3 and 15 mg orally. 3. The relevant haemodynamic values were obtained by means of an arterial catheter in the aorta, a venous catheter in the right atrium, and the measurement of cardiac output using the thermodilution method. 4. The antihypertensive efficacy of guanfacine was confirmed. 5. In the seven patients with a high peripheral resistance the main effect of guanfacine was a marked decrease in total peripheral resistance. In three patients with hypertension characterized by high stroke volume and cardiac output, the main effect of guanfacine was to reduce these variables.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6994767      PMCID: PMC1430111          DOI: 10.1111/j.1365-2125.1980.tb04920.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  1 in total

1.  Hemodynamic changes at rest and during exercise in long-term clonidine therapy of essential hypertension.

Authors:  P Lund-Johansen
Journal:  Acta Med Scand       Date:  1974 Jan-Feb
  1 in total
  2 in total

Review 1.  Central sympatholytic drugs.

Authors:  Wanpen Vongpatanasin; Kazuomi Kario; Steven A Atlas; Ronald G Victor
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-07-18       Impact factor: 3.738

Review 2.  Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-04       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.